drugset / Trial / NCT03968744

Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

NCT03968744

NaSingle-groupOpen-labelTreatment

Summary

Patients suffering of Parkinson's Disease will be treated with 50 mg/day of Safinamide per os for 2 weeks (escalation phase). Then, safinamide will be increased up to 100 mg/day and, if tolerated, the treatment will be taken for 10 more weeks (maintenance phase). Total treatment 12 weeks.

Timeline

Start
2019-02-18
Primary completion
2026-02-02
Completion
2026-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Safinamide Small molecule 100 mg Oral

Indications